ICP-B794 / InnoCare - LARVOL DELTA

InnoCare Pharma's novel ADC drug ICP-B794 has been successfully administered to its first patient [Google translation] (InnoCare Pharma Press Release)

Trial status • Solid Tumor

Evaluation of ICP-B794 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=410 | Not yet recruiting | Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

New P1 trial • Solid Tumor

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China (Businesswire) - "InnoCare Pharma...announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794....ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others."

New trial • Esophageal Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Prostate Cancer • Squamous Cell Carcinoma of Head and Neck